Synergy Pharmaceuticals, Inc. (SGYP) - NASDAQ
  • Tue, May 10, 5:02 PM
    | Tue, May 10, 5:02 PM | 19 Comments
  • Thu, Feb. 25, 5:25 PM
    | Thu, Feb. 25, 5:25 PM | 9 Comments
  • Nov. 9, 2015, 8:26 AM
    • Synergy Pharma (NASDAQ:SGYP): Q3 EPS of -$0.23 beats by $0.05.
    | Nov. 9, 2015, 8:26 AM | 1 Comment
  • Aug. 10, 2015, 5:14 PM
    • Synergy Pharma (NASDAQ:SGYP): Q2 EPS of -$0.34 misses by $0.06.
    | Aug. 10, 2015, 5:14 PM | 7 Comments
  • May 11, 2015, 5:24 PM
    • Synergy Pharma (NASDAQ:SGYP): Q1 EPS of -$0.28 misses by $0.01.
    | May 11, 2015, 5:24 PM
  • Mar. 17, 2015, 9:20 AM
    • Synergy Pharmaceuticals (SGYP +4.5%) Q4 results: Revenues: $0; R&D Expense: $24.6M (+50.0%); SG&A: $3M (+3.4%); Operating Loss: ($27.6M) (-42.3%); Net Loss: ($30.6M) (-53.8%); Loss Per Share: ($0.32) (-45.5%).
    • FY2014 results: Revenues: $0; R&D Expense: $83.3M (+64.6%); SG&A: $11M (-6.0%); Operating Loss: ($94.3M) (-51.4%); Net Loss: ($95.7M) (-54.1%); Loss Per Share: ($1.02) (-39.7%); Quick Assets: $196.4M (+188.0%).
    • No guidance given.
    | Mar. 17, 2015, 9:20 AM | 2 Comments
  • Mar. 16, 2015, 6:25 PM
    • Synergy Pharma (NASDAQ:SGYP): Q4 EPS of -$0.32 misses by $0.04.
    | Mar. 16, 2015, 6:25 PM | 4 Comments
  • Nov. 10, 2014, 4:23 PM
    • Synergy Pharma (NASDAQ:SGYP): Q3 EPS of -$0.24 beats by $0.04.
    | Nov. 10, 2014, 4:23 PM
  • Aug. 11, 2014, 6:07 PM
    • Synergy Pharmaceuticals (SGYP +5.9%) Q2 results: Revenues: $0; Net Loss: ($25.9M) (-159.0%); Loss Per Share: ($0.28) (-154.5%); Quick Assets: $51.2M (-24.9%).
    • No financial guidance given.
    | Aug. 11, 2014, 6:07 PM
  • Aug. 11, 2014, 5:44 PM
    • Synergy Pharma (NASDAQ:SGYP): Q2 EPS of -$0.28 may not be comparable to consensus of -$0.23.
    | Aug. 11, 2014, 5:44 PM
  • May 13, 2014, 7:36 AM
    • Synergy Pharma (SGYP): Q1 EPS of -$0.18 beats by $0.05.
    | May 13, 2014, 7:36 AM | 3 Comments
  • Mar. 17, 2014, 5:56 PM
    • Synergy Pharmaceuticals (SGYP): EPS of -$0.22 misses by $0.02.
    | Mar. 17, 2014, 5:56 PM
  • Aug. 9, 2013, 2:42 PM
    • Synergy Pharmaceuticals (SGYP -0.2%) posts a solid Q2 beat as losses for the quarter were less than expected.
    • Cash and equivalents balance as of June 30 was $92.3M , up from $32.5M at the end of December, 2012.
    • Announces plans to spin off the part of its business working on a shingles treatment as a separate publicly traded company.
    • The newly formed subsidiary, ContraVir Pharmaceuticals, will hold the FV-100 assets in order to capitalize on significant growth opportunities and provide greater focus on the respective businesses and strategic priorities.
    | Aug. 9, 2013, 2:42 PM | 1 Comment
  • Aug. 9, 2013, 9:13 AM
    • Synergy Pharmaceuticals (SGYP): Q2 EPS of -$0.11 beats by $0.12. (PR)
    | Aug. 9, 2013, 9:13 AM
  • May 9, 2013, 6:07 PM
    Synergy Pharmaceuticals (SGYP): Q1 EPS of -$0.26 misses by $0.10. (PR)
    | May 9, 2013, 6:07 PM
Company Description
Synergy Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of drugs to treat gastrointestinal disorders and diseases. Its lead product candidate includes plecanatide a phase 3 guanylate cyclase C, or GC-C, receptor agonist, designed to treat GI disorders,... More
Sector: Healthcare
Industry: Biotechnology
Country: United States